

Looking Ahead: Surveying the Changing Life Sciences Policy Landscape and its Effect on IP Due Diligence | Mercedes Meyer Joins Panel at ACI Life Sciences IP Due Diligence

Shareholder Mercedes Meyer will join the panel, “Looking Ahead: Surveying the Changing Life Sciences Policy Landscape and its Effect on IP Due Diligence,” at the ACI Life Sciences IP Due Diligence on Wednesday, December 4.

Mercedes and her co-panelists will provide insights into the shifting life sciences policy landscape. The panel will also cover:

- The impact of the Supreme Court’s decision in *Loper Bright Enterprises v. Raimondo* on regulatory agency determinations from the Food and Drug Administration (FDA), the US Patent and Trademark Office (USPTO), and the Federal Trade Commission (FTC)
- The significance of the FTC’s position on Orange Book delistings and how this may affect diligence reviews
- The impact of the government’s potential use of march-in rights on life sciences intellectual property and how this would affect IP value
- The impact of the PTO’s proposed rule on Terminal Disclaimers and the request for comments on the experimental use exception
- The Inflation Reduction Act and the challenges it presents to patent value
- Recent reforms to patent eligibility following the introduction of the Patent Eligibility Restoration Act
- Anticipation of the position of the next administration on life sciences IP rights, policies, and regulations

You can read more about this event by [clicking here](#).